For how we live.
Two phase 3 trials put the oral drug safiglipron ahead of placebo and non-inferior to dapagliflozin on HbA1c. Both ran only in China, were maker-funded, and showed dose-dependent gut side effects.
Tranexamic acid cut postpartum haemorrhage in placenta praevia. Dapagliflozin nearly halved acute kidney injury after cardiac surgery. The effect sizes are very different, and so is how much to trust them.
A meta-analysis of 90,000 people found these diabetes-origin drugs reduced kidney disease progression by 37% and cardiovascular events by 23%, and the benefit was similar in people who did not have diabetes.
The prices apply only to 10 drugs, only in Medicare, and only from January 2026. Here is exactly which drugs, by how much, and who actually sees the difference.
A first consolidated audit of PBS and PHARMAC cardiovascular listings from 2023 to 2025 finds a widening access gap between two neighbouring countries with similar disease burdens.
Dapagliflozin beat placebo on liver histology over 48 weeks in six Chinese hospitals. Weeks later, European regulators recommended the first purpose-built drug for the same disease.